

# Timothy J Henrich

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5594510/publications.pdf>

Version: 2024-02-01

93  
papers

5,211  
citations

109264

35  
h-index

98753

67  
g-index

106  
all docs

106  
docs citations

106  
times ranked

6903  
citing authors

#	ARTICLE	IF	CITATIONS
1	Lack of Antinuclear Antibodies in Convalescent Coronavirus Disease 2019 Patients With Persistent Symptoms. <i>Clinical Infectious Diseases</i> , 2022, 74, 2083-2084.	2.9	19
2	Long-term immunologic effects of SARS-CoV-2 infection: leveraging translational research methodology to address emerging questions. <i>Translational Research</i> , 2022, 241, 1-12.	2.2	15
3	Risk factors and abnormal cerebrospinal fluid associate with cognitive symptoms after mild COVID-19. <i>Annals of Clinical and Translational Neurology</i> , 2022, 9, 221-226.	1.7	53
4	Differences in Post-mRNA Vaccination Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Immunoglobulin G (IgG) Concentrations and Surrogate Virus Neutralization Test Response by Human Immunodeficiency Virus (HIV) Status and Type of Vaccine: A Matched Case-Control Observational Study. <i>Clinical Infectious Diseases</i> , 2022, 75, e916-e919.	2.9	42
5	Rapamycin limits CD4+ T cell proliferation in simian immunodeficiency virus-infected rhesus macaques on antiretroviral therapy. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	5
6	SARS-CoV-2 and Mitochondrial Proteins in Neural-Derived Exosomes of COVID-19. <i>Annals of Neurology</i> , 2022, 91, 772-781.	2.8	63
7	First-in-human immunoPET imaging of HIV-1 infection using 89Zr-labeled VRC01 broadly neutralizing antibody. <i>Nature Communications</i> , 2022, 13, 1219.	5.8	20
8	Role of antibodies, inflammatory markers, and echocardiographic findings in postacute cardiopulmonary symptoms after SARS-CoV-2 infection. <i>JCI Insight</i> , 2022, 7, .	2.3	24
9	Persistence, Magnitude, and Patterns of Postacute Symptoms and Quality of Life Following Onset of SARS-CoV-2 Infection: Cohort Description and Approaches for Measurement. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofab640.	0.4	56
10	Characterizing the COVID-19 Illness Experience to Inform the Study of Post-acute Sequelae and Recovery. <i>International Journal of Behavioral Medicine</i> , 2022, 29, 610-623.	0.8	9
11	COVID-19 in vaccinated versus unvaccinated hematologic malignancy patients. <i>Transplant Infectious Disease</i> , 2022, 24, .	0.7	4
12	CE-541-04 CARDIAC ARRHYTHMIAS IN POST-ACUTE SEQUELAE OF SARS-COV-2 INFECTION ASSESSED BY AMBULATORY RHYTHM MONITORING. <i>Heart Rhythm</i> , 2022, 19, S54-S55.	0.3	0
13	Markers of fungal translocation are elevated during post-acute sequelae of SARS-CoV-2 and induce NF- $\kappa$ B signaling. <i>JCI Insight</i> , 2022, 7, .	2.3	23
14	Plasma Markers of Neurologic Injury and Inflammation in People With Self-Reported Neurologic Postacute Sequelae of SARS-CoV-2 Infection. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2022, 9, .	3.1	41
15	Everolimus, an mTORC1/2 inhibitor, in ART-suppressed individuals who received solid organ transplantation: A prospective study. <i>American Journal of Transplantation</i> , 2021, 21, 1765-1779.	2.6	14
16	Treatment of immunocompromised COVID-19 patients with convalescent plasma. <i>Transplant Infectious Disease</i> , 2021, 23, e13477.	0.7	47
17	Total-Body PET Imaging in Infectious Diseases. <i>PET Clinics</i> , 2021, 16, 89-97.	1.5	9
18	Markers of Immune Activation and Inflammation in Individuals With Postacute Sequelae of Severe Acute Respiratory Syndrome Coronavirus 2 Infection. <i>Journal of Infectious Diseases</i> , 2021, 224, 1839-1848.	1.9	176

#	ARTICLE	IF	CITATIONS
19	Characterization and Biomarker Analyses of Post-COVID-19 Complications and Neurological Manifestations. <i>Cells</i> , 2021, 10, 386.	1.8	125
20	Persistent COVID-19-associated neurocognitive symptoms in non-hospitalized patients. <i>Journal of NeuroVirology</i> , 2021, 27, 191-195.	1.0	95
21	Evaluating a New Class of AKT/mTOR Activators for HIV Latency-Reversing Activity <i>Ex Vivo</i> and <i>In Vivo</i>. <i>Journal of Virology</i> , 2021, 95, .	1.5	13
22	Engineering luminescent biosensors for point-of-care SARS-CoV-2 antibody detection. <i>Nature Biotechnology</i> , 2021, 39, 928-935.	9.4	106
23	TNF-alpha inhibition in the setting of undiagnosed HIV infection. <i>Aids</i> , 2021, Publish Ahead of Print, 2163-2168.	1.0	2
24	SARS-CoV-2 seroprevalence, and IgG concentration and pseudovirus neutralising antibody titres after infection, compared by HIV status: a matched case-control observational study. <i>Lancet HIV</i> , the, 2021, 8, e334-e341.	2.1	99
25	Interpreting and addressing suboptimal immune responses after COVID-19 vaccination in solid organ transplant recipients. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	17
26	Discordant Virus-Specific Antibody Levels, Antibody Neutralization Capacity, and T-cell Responses Following 3 Doses of SARS-CoV-2 Vaccination in a Patient With Connective Tissue Disease. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab393.	0.4	3
27	SARS-CoV-2 antibody magnitude and detectability are driven by disease severity, timing, and assay. <i>Science Advances</i> , 2021, 7, .	4.7	117
28	Long-term SARS-CoV-2-specific immune and inflammatory responses in individuals recovering from COVID-19 with and without post-acute symptoms. <i>Cell Reports</i> , 2021, 36, 109518.	2.9	142
29	Genome-wide DNA methylation profiling of peripheral blood reveals an epigenetic signature associated with severe COVID-19. <i>Journal of Leukocyte Biology</i> , 2021, 110, 21-26.	1.5	82
30	Universal Polymerase Chain Reaction and Antibody Testing Demonstrate Little to No Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 in a Rural Community. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofaa531.	0.4	9
31	Circulating CD30+CD4+ T Cells Increase Before Human Immunodeficiency Virus Rebound After Analytical Antiretroviral Treatment Interruption. <i>Journal of Infectious Diseases</i> , 2020, 221, 1146-1155.	1.9	11
32	HIV-1 Coreceptor Usage and Variable Loop Contact Impact V3 Loop Broadly Neutralizing Antibody Susceptibility. <i>Journal of Virology</i> , 2020, 94, .	1.5	14
33	Cerebrospinal fluid soluble CD30 elevation despite suppressive antiretroviral therapy in individuals living with HIV-1. <i>Journal of Virus Eradication</i> , 2020, 6, 19-26.	0.3	6
34	A High Percentage of People With Human Immunodeficiency Virus (HIV) on Antiretroviral Therapy Experience Detectable Low-Level Plasma HIV-1 RNA Following Coronavirus Disease 2019 (COVID-19). <i>Clinical Infectious Diseases</i> , 2020, 73, e2845-e2846.	2.9	6
35	Biosensing: Tunable Fano-Resonant Metasurfaces on a Disposable Plastic-Template for Multimodal and Multiplex Biosensing ( <i>Adv. Mater.</i> 19/2020). <i>Advanced Materials</i> , 2020, 32, 2070151.	11.1	1
36	Clinical outcomes and serologic response in solid organ transplant recipients with COVID-19: A case series from the United States. <i>American Journal of Transplantation</i> , 2020, 20, 3225-3233.	2.6	60

#	ARTICLE	IF	CITATIONS
37	From Berlin to London: HIV-1 Reservoir Reduction Following Stem Cell Transplantation. <i>Current HIV/AIDS Reports</i> , 2020, 17, 385-393.	1.1	8
38	Tunable Fano-Resonant Metasurfaces on a Disposable Plastic Template for Multimodal and Multiplex Biosensing. <i>Advanced Materials</i> , 2020, 32, e1907160.	11.1	56
39	Differential decay of intact and defective proviral DNA in HIV-1-infected individuals on suppressive antiretroviral therapy. <i>JCI Insight</i> , 2020, 5, .	2.3	140
40	Cerebrospinal fluid soluble CD30 elevation despite suppressive antiretroviral therapy in individuals living with HIV-1. <i>Journal of Virus Eradication</i> , 2020, 6, 19-26.	0.3	3
41	Second example reported of a stem-cell transplant in the clinic leading to HIV remission. <i>Nature</i> , 2019, 568, 175-176.	13.7	1
42	Rapid development of HIV elite control in a patient with acute infection. <i>BMC Infectious Diseases</i> , 2019, 19, 815.	1.3	10
43	Seeing Is Believing: Nuclear Imaging of HIV Persistence. <i>Frontiers in Immunology</i> , 2019, 10, 2077.	2.2	17
44	Defining cerebrospinal fluid HIV RNA escape. <i>Aids</i> , 2019, 33, S107-S111.	1.0	40
45	CD32-RNA Co-localizes with HIV-RNA in CD3+ Cells Found within Gut Tissues from Viremic and ART-Suppressed Individuals. <i>Pathogens and Immunity</i> , 2019, 4, 147.	1.4	15
46	Elucidating the Burden of HIV in Tissues Using Multiplexed Immunofluorescence and In Situ Hybridization: Methods for the Single-Cell Phenotypic Characterization of Cells Harboring HIV In Situ. <i>Journal of Histochemistry and Cytochemistry</i> , 2018, 66, 427-446.	1.3	19
47	Dolutegravir intensification and HIV persistence: 3-1=3. <i>Lancet HIV</i> , 2018, 5, e201-e202.	2.1	3
48	Human Herpes Virus 8 in HIV-1 infected individuals receiving cancer chemotherapy and stem cell transplantation. <i>PLoS ONE</i> , 2018, 13, e0197298.	1.1	6
49	Transient loss of detectable HIV-1 RNA following brentuximab vedotin anti-CD30 therapy for Hodgkin lymphoma. <i>Blood Advances</i> , 2018, 2, 3479-3482.	2.5	14
50	NK-cell activation is associated with increased HIV transcriptional activity following allogeneic hematopoietic cell transplantation. <i>Blood Advances</i> , 2018, 2, 1412-1416.	2.5	2
51	Inconsistent HIV reservoir dynamics and immune responses following anti-PD-1 therapy in cancer patients with HIV infection. <i>Annals of Oncology</i> , 2018, 29, 2141-2142.	0.6	47
52	Progress towards obtaining an HIV cure. <i>Current Opinion in HIV and AIDS</i> , 2018, 13, 381-382.	1.5	3
53	Increased HIV-1 transcriptional activity and infectious burden in peripheral blood and gut-associated CD4+ T cells expressing CD30. <i>PLoS Pathogens</i> , 2018, 14, e1006856.	2.1	70
54	A humanized mouse-based HIV-1 viral outgrowth assay with higher sensitivity than in vitro qVOA in detecting latently infected cells from individuals on ART with undetectable viral loads. <i>Virology</i> , 2017, 507, 135-139.	1.1	43

#	ARTICLE	IF	CITATIONS
55	High-throughput Characterization of HIV-1 Reservoir Reactivation Using a Single-Cell-in-Droplet PCR Assay. <i>EBioMedicine</i> , 2017, 20, 217-229.	2.7	50
56	Human Immunodeficiency Virus Type 1 Persistence Following Systemic Chemotherapy for Malignancy. <i>Journal of Infectious Diseases</i> , 2017, 216, 254-262.	1.9	41
57	HIV-1 persistence following extremely early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: An observational study. <i>PLoS Medicine</i> , 2017, 14, e1002417.	3.9	186
58	International AIDS Society global scientific strategy: towards an HIV cure 2016. <i>Nature Medicine</i> , 2016, 22, 839-850.	15.2	395
59	Advances in biosensing strategies for HIV-1 detection, diagnosis, and therapeutic monitoring. <i>Advanced Drug Delivery Reviews</i> , 2016, 103, 90-104.	6.6	66
60	Ethics of ART interruption after stem-cell transplantation. <i>Lancet HIV</i> , 2016, 3, e8-e10.	2.1	20
61	CCR5- $\Delta 32$ Heterozygosity, HIV-1 Reservoir Size, and Lymphocyte Activation in Individuals Receiving Long-term Suppressive Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2016, 213, 766-770.	1.9	10
62	Real-Time Predictions of Reservoir Size and Rebound Time during Antiretroviral Therapy Interruption Trials for HIV. <i>PLoS Pathogens</i> , 2016, 12, e1005535.	2.1	85
63	A Woman with Dyspnea and Altered Mental Status. <i>New England Journal of Medicine</i> , 2016, 374, e29.	13.9	0
64	Printed Flexible Plastic Microchip for Viral Load Measurement through Quantitative Detection of Viruses in Plasma and Saliva. <i>Scientific Reports</i> , 2015, 5, 9919.	1.6	25
65	Viremic control and viral coreceptor usage in two HIV-1-infected persons homozygous for CCR5 $\Delta 32$ . <i>Aids</i> , 2015, 29, 867-876.	1.0	26
66	Designing and Interpreting Limiting Dilution Assays: General Principles and Applications to the Latent Reservoir for Human Immunodeficiency Virus-1. <i>Open Forum Infectious Diseases</i> , 2015, 2, ofv123.	0.4	119
67	Multitarget, quantitative nanoplasmonic electrical field-enhanced resonating device (NE) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 States of America, 2015, 112, E4354-63.	3.3	56
68	HIV eradication: is cord blood the answer?. <i>Lancet HIV</i> , 2015, 2, e219-e220.	2.1	2
69	Emerging Technologies for Point-of-Care Management of HIV Infection. <i>Annual Review of Medicine</i> , 2015, 66, 387-405.	5.0	97
70	Genome-Wide Association Study of Human Immunodeficiency Virus (HIV)-1 Coreceptor Usage in Treatment-Naive Patients from An AIDS Clinical Trials Group Study. <i>Open Forum Infectious Diseases</i> , 2014, 1, ofu018.	0.4	7
71	HIV-1 persistence in CD4+ T cells with stem cell-like properties. <i>Nature Medicine</i> , 2014, 20, 139-142.	15.2	379
72	Antiretroviral-Free HIV-1 Remission and Viral Rebound After Allogeneic Stem Cell Transplantation. <i>Annals of Internal Medicine</i> , 2014, 161, 319.	2.0	370

#	ARTICLE	IF	CITATIONS
73	Nanostructured Optical Photonic Crystal Biosensor for HIV Viral Load Measurement. Scientific Reports, 2014, 4, 4116.	1.6	144
74	HIV-1 entry inhibitors: recent development and clinical use. Current Opinion in Virology, 2013, 3, 51-57.	2.6	105
75	Early Treatment and HIV-1 Reservoirs: A Stitch in Time?. Journal of Infectious Diseases, 2013, 208, 1189-1193.	1.9	19
76	Long-Term Reduction in Peripheral Blood HIV Type 1 Reservoirs Following Reduced-Intensity Conditioning Allogeneic Stem Cell Transplantation. Journal of Infectious Diseases, 2013, 207, 1694-1702.	1.9	250
77	HIV-1 Clinical Isolates Resistant to CCR5 Antagonists Exhibit Delayed Entry Kinetics That Are Corrected in the Presence of Drug. Journal of Virology, 2012, 86, 1119-1128.	1.5	29
78	Low-level detection and quantitation of cellular HIV-1 DNA and 2-LTR circles using droplet digital PCR. Journal of Virological Methods, 2012, 186, 68-72.	1.0	133
79	Increased Risk of Virologic Rebound in Patients on Antiviral Therapy with a Detectable HIV Load <math>\geq 48</math> Copies/mL. PLoS ONE, 2012, 7, e50065.	1.1	45
80	Differential Use of CCR5 by HIV-1 Clinical Isolates Resistant to Small-Molecule CCR5 Antagonists. Antimicrobial Agents and Chemotherapy, 2012, 56, 1931-1935.	1.4	7
81	Impact of Age, Gender, and Pregnancy on Syphilis Screening Using the Captia Syphilis-G Assay. Sexually Transmitted Diseases, 2011, 38, 1126-1130.	0.8	10
82	SHIV-162P3 Infection of Rhesus Macaques Given Maraviroc Gel Vaginally Does Not Involve Resistant Viruses. PLoS ONE, 2011, 6, e28047.	1.1	12
83	Infectious Granulomatous Dermatitis Associated With <i>Rothia mucilaginosa</i> Bacteremia: A Case Report. American Journal of Dermatopathology, 2010, 32, 175-179.	0.3	18
84	Response to Shen and Siliciano. Clinical Infectious Diseases, 2010, 51, 1106-1107.	2.9	1
85	Xenotropic Murine Leukemia Virus-Related Virus Prevalence in Patients with Chronic Fatigue Syndrome or Chronic Immunomodulatory Conditions. Journal of Infectious Diseases, 2010, 202, 1478-1481.	1.9	60
86	Instantaneous Inhibitory Potential Is Similar to Inhibitory Quotient at Predicting HIV-1 Response to Antiretroviral Therapy. Clinical Infectious Diseases, 2010, 51, 93-98.	2.9	30
87	Evolution of CCR5 Antagonist Resistance in an HIV-1 Subtype C Clinical Isolate. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 55, 420-427.	0.9	23
88	Lymphoma Diagnosis and Plasma Epstein-Barr Virus Load during Vicriviroc Therapy: Results of the AIDS Clinical Trials Group A5211. Clinical Infectious Diseases, 2009, 48, 642-649.	2.9	18
89	Clinical Risk Factors for Severe <i>Clostridium difficile</i> -associated Disease. Emerging Infectious Diseases, 2009, 15, 415-422.	2.0	204
90	Association of Alcohol Abuse and Injection Drug Use with Immunologic and Virologic Responses to HAART in HIV-positive Patients from Urban Community Health Clinics. Journal of Community Health, 2008, 33, 69-77.	1.9	18

#	ARTICLE	IF	CITATIONS
91	Geographic dynamics of viral encephalitis in Thailand. <i>Microbes and Infection</i> , 2003, 5, 603-611.	1.0	15
92	Hantaan virus antibody prevalence in rodent populations of several provinces of northeastern Thailand. <i>Tropical Medicine and International Health</i> , 2002, 7, 840-845.	1.0	12
93	Rapid sequential development and rupture of mycotic aneurysms within a period of days in a patient with graft-versus-host disease and angiotropic <i>Scedosporium apiospermum</i> infection. , 0, 13, 242.		1